Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro Determination of Hydrolytic Enzymes and Echinocandin Susceptibility in Mexican Clinical Isolates of Candida glabrata Sensu Stricto

Rogelio de J. Treviño-Rangel 1 , José F. Espinosa-Pérez 1 , Hiram Villanueva-Lozano 1 , Laura A. Soto-Quintana 1 , Alexandra M. Montoya 1 , Carolina E. Luna-Rodríguez 1 and Gloria M. González 1 , *
Authors Information
1 Department of Microbiology, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico
Article information
  • Jundishapur Journal of Microbiology: 12 (6); e85092
  • Published Online: June 2, 2019
  • Article Type: Research Article
  • Received: October 8, 2018
  • Revised: May 17, 2019
  • Accepted: May 19, 2019
  • DOI: 10.5812/jjm.85092

To Cite: Treviño-Rangel R D J, Espinosa-Pérez J F, Villanueva-Lozano H, Soto-Quintana L A, Montoya A M, et al. In Vitro Determination of Hydrolytic Enzymes and Echinocandin Susceptibility in Mexican Clinical Isolates of Candida glabrata Sensu Stricto, Jundishapur J Microbiol. Online ahead of Print ; 12(6):e85092. doi: 10.5812/jjm.85092.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Alizadeh M, Kolecka A, Boekhout T, Zarrinfar H, Ghanbari Nahzag MA, Badiee P, et al. Identification of Candida species isolated from vulvovaginitis using matrix assisted laser desorption ionization-time of flight mass spectrometry. Curr Med Mycol. 2017;3(4):21-5. doi: 10.29252/cmm.3.4.21. [PubMed: 29707675]. [PubMed Central: PMC5917097].
  • 2. Esmailzadeh A, Zarrinfar H, Fata A, Sen T. High prevalence of candiduria due to non-albicans Candida species among diabetic patients: A matter of concern? J Clin Lab Anal. 2018;32(4). e22343. doi: 10.1002/jcla.22343. [PubMed: 29076587].
  • 3. Zarrinfar H, Kaboli S, Dolatabadi S, Mohammadi R. Rapid detection of Candida species in bronchoalveolar lavage fluid from patients with pulmonary symptoms. Braz J Microbiol. 2016;47(1):172-6. doi: 10.1016/j.bjm.2015.02.001. [PubMed: 26887241]. [PubMed Central: PMC4822774].
  • 4. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One. 2014;9(7). e101510. doi: 10.1371/journal.pone.0101510. [PubMed: 24991967]. [PubMed Central: PMC4081561].
  • 5. Correia A, Sampaio P, James S, Pais C. Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst Evol Microbiol. 2006;56(Pt 1):313-7. doi: 10.1099/ijs.0.64076-0. [PubMed: 16403904].
  • 6. Alcoba-Florez J, Mendez-Alvarez S, Cano J, Guarro J, Perez-Roth E, del Pilar Arevalo M. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol. 2005;43(8):4107-11. doi: 10.1128/JCM.43.8.4107-4111.2005. [PubMed: 16081957]. [PubMed Central: PMC1233986].
  • 7. Haynes K. Virulence in Candida species. Trends Microbiol. 2001;9(12):591-6. [PubMed: 11728872].
  • 8. Angoulvant A, Guitard J, Hennequin C. Old and new pathogenic Nakaseomyces species: Epidemiology, biology, identification, pathogenicity and antifungal resistance. FEMS Yeast Res. 2016;16(2):fov114. doi: 10.1093/femsyr/fov114. [PubMed: 26691882].
  • 9. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi: 10.1038/nrdp.2018.26. [PubMed: 29749387].
  • 10. Bizerra FC, Jimenez-Ortigosa C, Souza AC, Breda GL, Queiroz-Telles F, Perlin DS, et al. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob Agents Chemother. 2014;58(4):2438-40. doi: 10.1128/AAC.02189-13. [PubMed: 24468776]. [PubMed Central: PMC4023795].
  • 11. Green MR, Sambrook J. Isolation of high-molecular-weight DNA using organic solvents. Cold Spring Harb Protoc. 2017;2017(4):pdb prot093450. doi: 10.1101/pdb.prot093450. [PubMed: 28373491].
  • 12. White TJ, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols. San Diego: Academic Press; 1990. p. 315-22. doi: 10.1016/b978-0-12-372180-8.50042-1.
  • 13. Chakrabarti A, Nayak N, Talwar P. In vitro proteinase production by Candida species. Mycopathologia. 1991;114(3):163-8. [PubMed: 1886642].
  • 14. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia. 1982;20(1):7-14. [PubMed: 7038928].
  • 15. Slifkin M. Tween 80 opacity test responses of various Candida species. J Clin Microbiol. 2000;38(12):4626-8. [PubMed: 11101607]. [PubMed Central: PMC87648].
  • 16. Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities. J Clin Microbiol. 2001;39(8):2971-4. doi: 10.1128/JCM.39.8.2971-2974.2001. [PubMed: 11474025]. [PubMed Central: PMC88272].
  • 17. Koga-Ito CY, Lyon JP, Vidotto V, de Resende MA. Virulence factors and antifungal susceptibility of Candida albicans isolates from oral candidosis patients and control individuals. Mycopathologia. 2006;161(4):219-23. doi: 10.1007/s11046-005-0001-x. [PubMed: 16552484].
  • 18. Trevino-Rangel RJ, Espinosa-Perez JF, Villanueva-Lozano H, Montoya AM, Andrade A, Bonifaz A, et al. First report of Candida bracarensis in Mexico: Hydrolytic enzymes and antifungal susceptibility pattern. Folia Microbiol (Praha). 2018;63(4):517-23. doi: 10.1007/s12223-018-0592-5. [PubMed: 29488180].
  • 19. Rex JH. Reference method for broth dilution antifungal susceptibility testing of yeasts. 4th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
  • 20. Aktas E, Yigit N, Ayyildiz A. Esterase activity in various Candida species. J Int Med Res. 2002;30(3):322-4. doi: 10.1177/147323000203000315. [PubMed: 12166351].
  • 21. Kantarcioglu AS, Yucel A. Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains. Mycoses. 2002;45(5-6):160-5. [PubMed: 12100532].
  • 22. Rodrigues AG, Pina-Vaz C, Costa-de-Oliveira S, Tavares C. Expression of plasma coagulase among pathogenic Candida species. J Clin Microbiol. 2003;41(12):5792-3. doi: 10.1128/jcm.41.12.5792-5793.2003. [PubMed: 14662985]. [PubMed Central: PMC308979].
  • 23. Gokce G, Cerikcioglu N, Yagci A. Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures. Mycopathologia. 2007;164(6):265-9. doi: 10.1007/s11046-007-9053-4. [PubMed: 17874282].
  • 24. Oksuz S, Sahin I, Yildirim M, Gulcan A, Yavuz T, Kaya D, et al. Phospholipase and proteinase activities in different Candida species isolated from anatomically distinct sites of healthy adults. Jpn J Infect Dis. 2007;60(5):280-3. [PubMed: 17881867].
  • 25. Yigit N, Aktas AE, Ayyildiz A. Detection of coagulase activity in pathogenic Candida species. J Int Med Res. 2008;36(6):1378-82. doi: 10.1177/147323000803600627. [PubMed: 19094449].
  • 26. D'Eca Junior A, Silva AF, Rosa FC, Monteiro SG, de Maria Silva Figueiredo P, de Andrade Monteiro C. In vitro differential activity of phospholipases and acid proteinases of clinical isolates of Candida. Rev Soc Bras Med Trop. 2011;44(3):334-8. [PubMed: 21901875].
  • 27. Chin VK, Foong KJ, Maha A, Rusliza B, Norhafizah M, Ng KP, et al. Candida albicans isolates from a Malaysian hospital exhibit more potent phospholipase and haemolysin activities than non-albicans Candida isolates. Trop Biomed. 2013;30(4):654-62. [PubMed: 24522136].
  • 28. Tellapragada C, Eshwara VK, Johar R, Shaw T, Malik N, Bhat PV, et al. Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis. J Pathog. 2014;2014:142864. doi: 10.1155/2014/142864. [PubMed: 25110589]. [PubMed Central: PMC4119684].
  • 29. Deorukhkar SC, Saini S, Mathew S. Non-albicans Candida infection: An emerging threat. Interdiscip Perspect Infect Dis. 2014;2014:615958. doi: 10.1155/2014/615958. [PubMed: 25404942]. [PubMed Central: PMC4227454].
  • 30. Mutlu Sariguzel F, Berk E, Koc AN, Sav H, Demir G. Investigation of the relationship between virulence factors and genotype of Candida spp. isolated from blood cultures. J Infect Dev Ctries. 2015;9(8):857-64. doi: 10.3855/jidc.5359. [PubMed: 26322878].
  • 31. Atalay MA, Koc AN, Demir G, Sav H. Investigation of possible virulence factors in Candida strains isolated from blood cultures. Niger J Clin Pract. 2015;18(1):52-5. doi: 10.4103/1119-3077.146979. [PubMed: 25511344].
  • 32. Riceto EB, Menezes Rde P, Penatti MP, Pedroso Rdos S. Enzymatic and hemolytic activity in different Candida species. Rev Iberoam Micol. 2015;32(2):79-82. doi: 10.1016/j.riam.2013.11.003. [PubMed: 24704439].
  • 33. Figueiredo-Carvalho MHG, Ramos LS, Barbedo LS, de Oliveira JCA, Dos Santos ALS, Almeida-Paes R, et al. Relationship between the antifungal susceptibility profile and the production of virulence-related hydrolytic enzymes in Brazilian clinical strains of Candida glabrata. Mediators Inflamm. 2017;2017:8952878. doi: 10.1155/2017/8952878. [PubMed: 28814823]. [PubMed Central: PMC5549490].
  • 34. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288-305. doi: 10.1111/j.1574-6976.2011.00278.x. [PubMed: 21569057].
  • 35. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62(Pt 1):10-24. doi: 10.1099/jmm.0.045054-0. [PubMed: 23180477].
  • 36. Pakshir K, Zomorodian K, Karamitalab M, Jafari M, Taraz H, Ebrahimi H. Phospholipase, esterase and hemolytic activities of Candida spp. isolated from onychomycosis and oral lichen planus lesions. J Mycol Med. 2013;23(2):113-8. doi: 10.1016/j.mycmed.2013.04.007. [PubMed: 23706304].
  • 37. Luo G, Samaranayake LP, Cheung BP, Tang G. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of HLP gene expression in Candida glabrata and its possible role in in vitro haemolysin production. APMIS. 2004;112(4-5):283-90. doi: 10.1111/j.1600-0463.2004.apm11204-0509.x. [PubMed: 15233644].
  • 38. Srivastava VK, Suneetha KJ, Kaur R. A systematic analysis reveals an essential role for high-affinity iron uptake system, haemolysin and CFEM domain-containing protein in iron homoeostasis and virulence in Candida glabrata. Biochem J. 2014;463(1):103-14. doi: 10.1042/BJ20140598. [PubMed: 24987864].
  • 39. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724-32. doi: 10.1093/cid/cit136. [PubMed: 23487382]. [PubMed Central: PMC3658363].
  • 40. Morales-Lopez S, Dudiuk C, Vivot W, Szusz W, Cordoba SB, Garcia-Effron G. Phenotypic and molecular evaluation of echinocandin susceptibility of Candida glabrata, Candida bracarensis, and Candida nivariensis strains isolated during 30 years in Argentina. Antimicrob Agents Chemother. 2017;61(7). doi: 10.1128/AAC.00170-17. [PubMed: 28461313]. [PubMed Central: PMC5487631].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments